Skip to main content
European Commission logo print header

Leveraging room temperature diamond quantum dynamics to enable safe, first-of-its-kind, multimodal cardiac imaging

Project description

Metabolic MRI for cardiovascular disease diagnosis

Molecular characterisation of tissues is necessary to understand disease pathophysiology. Positron emission tomography (PET) is the only imaging modality that measures the metabolic activity of cells within tissues, but it is not suitable for understanding and characterising cardiovascular diseases. To address this limitation, the EU-funded MetaboliQs project has developed a novel method for magnetic resonance imaging (MRI) that provides information on the chemical state of the tissue. The method amplifies the MRI signal of metabolites by a thousand-fold generating important insight into metabolic activity at a fraction of the cost. The MetaboliQs method is expected to unlock novel diagnostic capabilities and advance personalised treatment of cardiovascular and other metabolic diseases.

Objective

Cardiovascular Diseases (CVDs) are the number 1 cause of death globally: more people die annually from CVDs than from any other cause. Despite emerging diagnostics tools and therapeutics, several areas of significant unmet need remain unaddressed among CVD patients. The ability to personalize cardiovascular medical care and improve outcomes, will require characterization of disease processes at a molecular level. The current state-of-the-art, e.g. Positron emission tomography (PET), does not provide detailed information about the chemical state of the tissue at a molecular level, therefore it remains difficult to accurately diagnose and confidently select appropriate therapy in many circumstances. The MetaboliQs project brings together two areas of European excellence - diamond-based quantum sensing and medical imaging. We will translate a newly developed hyperpolarization method for magnetic resonance imaging (MRI) based on the quantum dynamics of nitrogen-vacancy (NV) centers. This breakthrough quantum technology will enable previously unachievable, highly sensitive quantification of metabolic activity, paving the way for precision diagnostics and better personalized treatment of cardiovascular and other metabolic diseases. For realizing and eventually commercializing the technology, MetaboliQs brings together a world-class multidisciplinary consortium with end to end expertise - leading diamond quantum technology research institutes (Fraunhofer IAF - quantum-grade diamond growth and fabrication, HUJI - quantum sensing) and innovative companies (Element 6 - worldwide leader in synthetic diamonds, NVision - inventor of diamond-based polarization), as well as two expert users of hyperpolarized and cardiovascular MRI (TUM, ETH Zurich - first in continental Europe to conduct clinical trials of hyperpolarized MRI for cardiovascular disease) and the market leader in electron paramagnetic resonance and preclinical MRI (Bruker).

Call for proposal

H2020-FETFLAG-2018-2020

See other projects for this call

Sub call

H2020-FETFLAG-2018-03

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Net EU contribution
€ 1 500 172,50
Address
Hansastrasse 27c
80686 Munchen
Germany

See on map

Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
€ 1 500 172,50

Participants (6)